Susana Banerjee
A5065447416- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Genetic factors in colorectal cancer
- Advances in Oncology and Radiotherapy
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Chromatin Remodeling and Cancer
- Renal cell carcinoma treatment
- Monoclonal and Polyclonal Antibodies Research
- Angiogenesis and VEGF in Cancer
- Intraperitoneal and Appendiceal Malignancies
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Endometriosis Research and Treatment
- CAR-T cell therapy research
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2016-2025
National Cancer Research Institute
2017-2025
Royal Marsden Hospital
2016-2025
Sriram Chandra Bhanja Medical College Hospital
2025
KU Leuven
2019-2024
Spanish Ovarian Cancer Research Group
2024
University Medical Center Hamburg-Eppendorf
2024
Centre Hospitalier Universitaire de Liège
2024
Universität Hamburg
2024
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers HER2-mutant non–small-cell lung cancer. Treatments are limited for other solid tumors. METHODS This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced metastatic disease after ≥1 systemic treatment without alternative...
Deficient mismatch mutation repair mechanisms may sensitize endometrial cancers to anti-programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an investigational anti-PD-1 antibody that binds with high affinity the PD-1 receptor.To assess antitumor activity and safety of dostarlimab for patients deficient cancer.This ongoing, open-label, single-group, multicenter study began part on March 7, 2016, enrolling cancer May 8, 2017. Median follow-up was 11.2 months (range, 0.03 [ongoing]...
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients newly diagnosed advanced ovarian cancer and BRCA1 and/or BRCA2 (BRCA) mutation. We report overall (OS) after 7-year follow-up, clinically relevant time point longest follow-up for any first-line setting.This double-blind phase III trial randomly assigned BRCA mutation clinical response to...
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in control as public priority, passing the World Health Assembly Resolution 70.12 prevention within an integrated approach. this manuscript, 2016 European Society for Medical Oncology Leadership Generation Programme participants propose strategic framework that line with 2017 WHO Cancer consistent...
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, potent tubulin-targeting agent. The randomized, open-label, phase III study FORWARD I compared MIRV investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC).Eligible 1-3 prior lines of therapy whose tumors were positive for FRα expression randomly assigned, 2 : 1 ratio, to receive (6...
Abstract Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of processes are impeding realisation patient benefits. Ovarian cancer exemplifies the potential value shortcomings current pathways to access testing. Approximately 15% ovarian patients a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management that relatives. Unfortunately, most countries, routine implementation BRCA been inconsistent largely...
Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free overall survival with dose-dense weekly 3-weekly carboplatin. In this study, we aimed to compare efficacy safety of two regimens standard predominantly European population
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in United States.We conducted phase 3, global, confirmatory, open-label, randomized, controlled trial to compare efficacy and safety MIRV with investigator's choice chemotherapy platinum-resistant, high-grade serous cancer. Participants who had previously received one three lines therapy high FRα tumor expression...